Disintegrating tablets comprising licarbazepine

Details for Australian Patent Application No. 2005226909 (hide)

Owner Novartis AG

Inventors Wolf, Marie-Christine; Kalb, Oskar

Agent Davies Collison Cave

Pub. Number AU-B-2005226909

PCT Pub. Number WO2005/092290

Priority 0406381.4 22.03.04 GB; 0406737.7 25.03.04 GB

Filing date 21 March 2005

Wipo publication date 6 October 2005

Acceptance publication date 14 May 2009

International Classifications

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

C07D 223/00 (2006.01) Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom

Event Publications

14 September 2006 PCT application entered the National Phase

  PCT publication WO2005/092290 Priority application(s): WO2005/092290

14 May 2009 Application Accepted

  Published as AU-B-2005226909

10 September 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005226910-Oral matrix formulations comprising licarbazepine

2005226906-Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure